Peter Halling has been appointed CEO of Fertin Pharma and will join in August 2020.
Peter brings extensive experience from working in international environments of production companies in complex and contract-driven markets. He most recently served as an Executive Vice President at Döhler Group but prior to that held various roles at Ingredion and Novozymes. With his background he will be well-suited to guide and support Fertin on its exciting journey ahead.
After more than a decade at the helm shaping Fertin into a world leading specialised CDMO in innovative oral and intra-oral delivery systems, Søren Birn has decided to resign as CEO. He will remain committed to Fertin for a transition period and after that remain available for consulting for the new CEO, Board of Directors and owners.
Marianne Kirkegaard, Chair of Fertin, commented: “On behalf of the entire Board of Directors, I would like to thank Søren for his loyal contribution over the years. During Søren’s long tenure as CEO, he has been instrumental in shaping Fertin to the successful company it is today. As a company, our mission in life is to ‘support healthier living’ and under Søren’s leadership we have successfully embarked on a strategy to do exactly that. With Peter on board as our new CEO, I am confident that Fertin will continue to deliver on our mission and I look very much forward to working with Peter and the team during the next exciting phase of Fertin’s journey!”
Peter Halling said: “I’m excited to join Fertin – it is a well-managed company with a unique set of competences and strong track-record of innovation. I look forward to continuing Fertin’s growth journey by servicing our existing and new customers, introducing new products and driving operational excellence. I strongly believe in Fertin’s vision, to support healthier living, and look forward to commencing in August”.